News

UK National Health Service Drives to Detect Liver Cancer

FDA Brief: Edison Histotripsy System Granted Marketing Authorization for Treatment of Liver Tumors

Are Patients With Autoimmune Hepatitis at Risk for Hepatocellular Carcinoma?

Atezolizumab Plus Bevacizumab After Surgery for High-Risk Liver Cancer: Phase III Results

SBRT for Early-Stage Solitary Hepatocellular Carcinoma: A View From Australia

When Tissue Is Not Available in Liver Cancer, What About Plasma-Based Molecular Profiling?

Sarcopenia and Visceral Adiposity: Can They Improve Prediction of Liver Cancer Prognosis?

Chemotherapies Compared in Intrahepatic Cholangiocarcinoma: Retrospective View of ABC Trials

FDA Approves Pembrolizumab Plus Chemotherapy for Biliary Tract Cancer

ESMO 2023: FGFR Inhibitor Under Study in Advanced Cholangiocarcinoma

ESMO 2023: Does Location of Extrahepatic Cholangiocarcinoma Affect Chemotherapy Outcomes?

ESMO 2023: Triplet Immunotherapy Regimen Under Study in Advanced Liver Cancer

Does Liver Transplantation Offer Survival Benefit in Patients With Hepatocellular Carcinoma?

Are High-Risk Colon Polyps Linked to Higher Mortality From Liver Cancer?

Is Laparoscopic Cholecystectomy Safer Than Robotic-Assisted Cholecystectomy?

ASTRO 2023: Predicting Local Control With Hypofractionated Radiotherapy in Liver Cancer

ASTRO 2023: Safety of SPECT-Guided Ablative Radiotherapy for Liver Cancers

Could Neuroprotective Protein Play a Role in Progression of Liver Cancer?

Genetic Variants Linked to Prognosis in Patients With Intrahepatic Cholangiocarcinoma

Do Race and Ethnicity Play a Role in the Etiology of Liver Cancer?

Unusual Case of Autoimmune Hepatitis Plus Primary Biliary Cholangitis With Atypical Liver Cancer

Cirrhosis and Liver Cancer in West Africa: Focus on Use of Tenofovir Disoproxil Fumarate

How Cholangiocarcinoma Differs in Adolescent and Younger Adults Versus Older Adults

Comparing Thermal Ablation and SBRT for Hepatocellular Carcinoma

Which Patients With Cholangiocarcinoma May Benefit From Perioperative Chemotherapy?

Impact of Tislelizumab Versus Sorafenib on Quality of Life in Hepatocellular Carcinoma

ASCOBT 2023: Novel Strategy for Delivering Immunotherapy Under Study in Liver Cancer

ASCOBT 2023: Investigating Hypoxia-Induced Mechanisms of PD-L1 Inhibitor Resistance in Liver Cancer

Phase III Results Support Novel Combination for Unresectable Hepatocellular Carcinoma

FDA Grants Orphan Drug Designation to Kinase Inhibitor in Treatment of Cholangiocarcinoma

ASCOBT 2023: Does Postoperative Microvascular Invasion Impact Outcomes in Hepatocellular Carcinoma?

Researchers Identify Alterations in Ammonia Metabolic Pathways in Fibrolamellar Liver Cancer

ASCOBT 2023: Can Serum-Based Parameters Predict Outcomes in Unresectable Liver Cancer?

ASCOBT 2023: Is the Gut Microbiome a Key to Predicting Immunotherapy Response in Liver Cancer?

ASCOBT 2023: Study Identifies Potential Therapeutic Target in Gallbladder Cancer

Zanidatamab Immunotherapy for HER2-Positive Advanced Biliary Tract Cancer

Researchers Use Genomics to Inform the Creation of New Model for Pediatric Hepatoblastoma

Can Regular Statin Use Reduce the Risk of Hepatocellular Carcinoma?

Adagrasib Active in Variety of KRAS G12C–Mutated Tumors, Including Biliary Tract Cancer

Trio of Immune Cells Within Tumor Niches May Be Linked to Immunotherapy Response in Liver Cancer

Novel Bispecific Antibody Under Study in Advanced Biliary Tract Cancers

Early Dose-Escalation Data Confirm Potential of FGFR2 Inhibitor in Liver Cancer

ASCO 2023: Adding Sintilimab and Anlotinib to Chemotherapy for Advanced Biliary Tract Cancer

ASCO 2023: Can Neoadjuvant FOLFOX-HAIC Improve Outcomes After Hepatectomy?

ASCO 2023: Identifying Potentially Targetable Gene Mutations in Intrahepatic Cholangiocarcinoma

ASCO 2023: Phase II Trial Assesses Combination Strategies for Treating Gallbladder Adenocarcinoma

ASCO 2023: Quality-of-Life Data With Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer

ASCO 2023: Combination Therapy With Olaparib Plus Pembrolizumab in Biliary Tract Cancers

ASCO 2023: Consolidation Chemoradiotherapy Versus Observation After Chemotherapy for Gallbladder Cancer

ASCO 2023: Zanidatamab Therapy for Refractory HER2-Amplified Biliary Tract Cancer

ASCO 2023: Impact of Immune-Mediated Adverse Events on STRIDE Outcomes in Unresectable Liver Cancer